AccessibilityHelpAbout Us
Cannara Biotech logo

Cannara Biotech(OTC) LOVFF

Market Cap$141.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-20%
5 Year+19%
1 Year+14%
1 Month-0%
$1.43
-0.14%
-0.00Today
Cannara Biotech last closing stock price
MetricPriceDate
Last closeUSD 1.432026-09-17
Cannara Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.28%USD 1.432026-09-10
1 month-0.14%USD 1.432026-08-18
3 month+23.32%USD 1.162026-06-17
Year to date+12.44%USD 1.272025-12-30
1 year+13.51%USD 1.262025-09-17
3 year+99.16%USD 0.722023-09-18
5 year+19%USD 1.202021-09-17
Since inception-20.31%USD 1.792019-01-18

Cannara Biotech Financials at a Glance

Market Cap

$141.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$117.76M

Net Income (TTM)

CA$10.86M

EPS (TTM)

$0.08

P/E Ratio

17.29

Dividend

$0.00

Beta (Volatility)

0.05 (Low)

Price

$1.43

Volume

12,250

Open

$1.43

Previous Close

$1.43

Daily Range

$1.43 - $1.44

52-Week Range

$1.11 - $1.47

Estimated Earnings Date

Nov 23, 2026

LOVFF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cannara Biotech

Cannara Biotech Inc. is a Canadian company engaged in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products. The company operates in two segments: Cannabis operations and Real estate operations, offering products under the TRIBAL, nugz, and ORCHID CBD brand names.

Products and Services
  • Indoor cultivation of high-quality cannabis
  • Processing and sale of cannabis-derivative products
  • Real estate operations related to cannabis facilities
Growth Outlook
  • Revenue increased to CAD 31.83 million in Q3 2026
  • Gross profit margin improved to 47.23% in Q3 2026
  • Strong demand for cannabis products supports future growth
Financial Highlights
  • Net income of CAD 4.84 million in Q3 2026
  • Operating income ratio of 23.12% in Q3 2026
  • Current ratio of 2.99 indicates strong liquidity position
Cannara Biotech Inc. has demonstrated significant growth in revenue, with a notable increase to CAD 31.83 million in the most recent quarter. The gross profit margin has also shown improvement, reaching 47.23%, reflecting effective cost management and operational efficiency. The company’s strong demand for its cannabis products positions it well for future growth, particularly as the market continues to expand. Financially, Cannara reported a net income of CAD 4.84 million in Q3 2026, showcasing its ability to generate profit amidst a competitive landscape. The operating income ratio of 23.12% further highlights the company's operational effectiveness. Additionally, a current ratio of 2.99 indicates a robust liquidity position, allowing for flexibility in meeting short-term obligations. Overall, Cannara Biotech Inc. presents a compelling opportunity within the cannabis industry, backed by strong financial performance and a strategic focus on growth.
AI Generated • Sep 15, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

452

CEO

Zohar Krivorot

Website

www.cannara.ca

Headquarters

Saint-Laurent, QC H4N 3M9, CA

LOVFF Financials

Key Financial Metrics (TTM)

Gross Margin

26.30%

Operating Margin

0.10%

Net Income Margin

9.22%

Return on Equity

9.45%

Return on Capital

15.44%

Return on Assets

5.58%

Earnings Yield

5.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$141.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

98.78M

Volume

12.25K

Avg. Volume

11.16K

Financials (TTM)

Gross Profit

CA$50.40M

Operating Income

CA$18.78M

EBITDA

CA$25.22M

Operating Cash Flow

CA$19.42M

Capital Expenditure

-CA$13.72M

Free Cash Flow

CA$5.70M

Cash & ST Invst.

CA$15.80M

Total Debt

CA$26.97M

Cannara Biotech Performance Analysis

Cannara Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-08-31CAD 28,175,752N/A
20232023-08-31CAD 42,519,07650.9%
20242024-08-31CAD 60,077,01141.3%
20252025-08-31CAD 76,812,65927.9%
Cannara Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-08-314.8%
Q12025-11-305.2%
Q22026-02-28-9.7%
Q32026-05-3117.1%
Cannara Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-08-31CAD 0.02N/A
20232023-08-31CAD 0.06180.6%
20242024-08-31CAD 0.05-10.4%
20252025-08-31CAD 0.1095.8%
Cannara Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-08-31-9.5%
Q12025-11-30-70.2%
Q22026-02-2885.2%
Q32026-05-31150.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$31.83M

+16.4%

Gross Profit

CA$15.03M

+16.7%

Gross Margin

47.23%

N/A

Market Cap

$141.06MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$312.08K

N/A

Employees

452

N/A

Net Income

CA$4.84M

+16.9%

EBITDA

CA$8.99M

+11.8%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$15.80M

+9.7%

Total Debt

CA$26.97M

-43.2%

Accounts Receivable

CA$13.42M

-4.8%

Inventory

CA$40.31M

-17.7%

Long Term Debt

CA$19.73M

-42.2%

Short Term Debt

CA$7.24M

-45.6%

Return on Assets

5.58%

N/A

Return on Invested Capital

0.07%

N/A

Free Cash Flow

CA$1.28M

-89.1%

Operating Cash Flow

CA$5.68M

-59.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BIOYFBioSyent Inc.
$11.25-1.32%
GRUSFGrown Rogue International Inc.
$0.42-2.74%
HLTRFHLS Therapeutics Inc.
$2.82+0.00%
ORXOYOrexo AB (publ)
$1.39+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About LOVFF

What is the current price of Cannara Biotech?

Cannara Biotech is trading at $1.43 per share.

What is the 52-week range for Cannara Biotech?

Over the past 52 weeks, Cannara Biotech has traded between $1.11 and $1.47.

How much debt does Cannara Biotech have?

As of the most recent reporting period, Cannara Biotech reported total debt of CA$26.86M.

How much cash does Cannara Biotech have on hand?

Cannara Biotech reported CA$15.83M in cash and cash equivalents in its most recent financial results.

What is Cannara Biotech’s dividend yield?

Cannara Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services